Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 12,976	$ 11,109
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	5,291	5,193
Stock based compensation	845	817
Asset write-downs	198	1,019
Contingent consideration reversal	(1,148)	0
Net gain on sale of assets/businesses	(60)	(2,125)
Deferred tax provision	(238)	(2,126)
Credit losses and accounts receivable allowances	74	(15)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(440)	(665)
Increase in inventories	(784)	(424)
(Decrease)/Increase in accounts payable and accrued liabilities	(119)	2,273
Increase in other current and non-current assets	(1,983)	(81)
Increase in other current and non-current liabilities	581	2,043
NET CASH FLOWS FROM OPERATING ACTIVITIES	15,193	17,018
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(2,024)	(2,238)
Proceeds from the disposal of assets/businesses, net	100	3,103
Acquisitions, net of cash acquired	(949)	(5,562)
Purchases of investments	(16,243)	(2,684)
Sales of investments	6,585	2,459
Proceeds from credit support agreements, net	125	0
Other (primarily licenses and milestones)	(516)	72
NET CASH USED BY INVESTING ACTIVITIES	(12,922)	(4,850)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(7,823)	(7,417)
Repurchase of common stock	(2,900)	(6,320)
Proceeds from short-term debt	3,335	148
Repayment of short-term debt	(310)	(87)
Proceeds from long-term debt, net of issuance costs	7,431	1
Repayment of long-term debt	(562)	(1,008)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	922	580
Other	(569)	160
NET CASH USED BY FINANCING ACTIVITIES	(476)	(13,943)
Effect of exchange rate changes on cash and cash equivalents	(135)	(83)
Increase/(Decrease) in cash and cash equivalents	1,660	(1,858)
Cash and Cash equivalents, beginning of period	17,305	18,107
Cash and Cash equivalents, end of period	18,965	16,249
Acquisitions
Fair value of assets acquired	1,173	6,861
Fair value of liabilities assumed and noncontrolling interests	(224)	(1,299)
Net cash paid for acquisitions	949	$ 5,562
Auris Health
Adjustments to reconcile net earnings to cash flows from operating activities:
Contingent consideration reversal	$ (1,148)